Date of Preparation: 8/1997


Invited and/or Refereed Internationally or Nationally



Yüklə 231,71 Kb.
səhifə3/4
tarix04.11.2017
ölçüsü231,71 Kb.
#30662
1   2   3   4

Invited and/or Refereed Internationally or Nationally:

1. Martino S, Ownby H, Russo J, Roi L, Brennen MJ. "Interrupted Pregnancy as an Indicator of Prognosis in Primary Breast Cancer". 5th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, November 5 6, 1982.


2. Martino S. "Therapy of Breast Cancer". The 9th Annual Modern Oncology for General Practitioners, (sponsored by American Cancer Society and the Florida Osteopathic Medical Association), Ft. Lauderdale, Florida, September 6 7, 1984.
3. Martino S. "Breast Cancer". "The Science of Aging". American College of Osteopathic Internists, 44th Annual Convention and Scientific Sessions, Lake Buena Vista, Florida, October 14 19, 1984.
4. Schilcher RB, Decker D, Evans LJ, Martino S, Kresge C, Young JD, Samal, B.A., Singhakowinta, A. "Influence of Age on Pharmacokinetics of 5 Fluorouracil (5FU)." 7th Annual Breast Cancer Symposium, December 7 8, 1984, San Antonio, Texas.
5. Martino, S., Ratanatharathorn, V., Karanes, C., Samal, B.A., Sohn, Y.S., Rudnick, S.E. "Reversible Arrhythmias Observed in Patients Treated with Recombinant DNA Alpha 2 Interferon." 7th Annual San Antonio Breast Cancer Symposium, December 7 8, 1984, San Antonio, Texas.


  1. Martino, S., Schilcher, R.B., Marier, S.J., Evans, L.F., Allen, B.J., Young, J.D. "Clinical and Pharmacokinetic

Results in a Breast Cancer Patient with Hyperbilirubinemia Treated with Doxorubicin (DOX)." 7th Annual

Breast Cancer Symposium, December 7 8, 1984, San Antonio, Texas.
7. Martino, S. "4`Deoxydoxorubicin as First Line Therapy for Metastatic Breast Cancer". 8th Annual San Antonio Breast Cancer Symposium, November 7 8, 1985, San Antonio, Texas.
8. Martino, S. "Ovarian Function with use of LHRH Agonists in Women with Breast Cancer." Developmental Therapeutics Symposium. SWOG meeting February 23, 1986, San Antonio, Texas.
9. Martino, S. "Cancer of the Breast: Radical Mastectomy vs. Lumpectomy; The Role of Mammography". Fourth Annual Joint Session of the American Osteopathic Association and Upjohn Company, November 6, 1986, Las Vegas, Nevada.


  1. Martino, S. "4 Nitroestrone 3 Methyl Ether". Development Therapeutics Symposium SWOG meeting, Columbus, Ohio, September, 15 17, 1987.



  1. Martino, S. "Chemotherapy of Breast Cancer". American College of Physician's Postgraduate Course, Medical Oncology Board Review Course, Columbus, Ohio, September 15 17, 1987.

12. Martino, S. "A Breast Cancer Prevention Trial   Clinical and Scientific Studies" at Experimental Therapeutics Symposium, SWOG. October 24, 1988.


13. Flaherty, L., Redman, B., Martino, S., Valdivieso, M., Rudolph, A. "Sequential recombinant interleukin 2 (rIL 2) and dacarbazine (DTIC) (RID 1) in metastatic malignant melanoma (MMM) clinical and immunologic results". Society for Biological Therapy, November 6 11, 1988.
14. Redman, B., Flaherty, L., Chou, T.H., Martino, S., Al Katib, A., Kaplan, J., Valdivieso, M. "Phase I trial of combination therapy with recombinant interleukin 2 (IL 2) and recombinant interferon gamma (IFN  ) in patients with cancer". Society for Biological Therapy, November 6 11, 1988.
15. Martino, S., Gala, R., Valeriote, F., Kim, P., Heilbrun, L., Kresge, C., Boomer, A. "Prolactin as a predictor of breast cancer risk". 11th Annual San Antonio Breast Cancer Symposium, Texas, November 29 30, 1988.
16. Ensley, J., An, T., Martino, S., Weaver, D., Benitez, P., Valeriote, F., Heilbrun, L. "Flow cytometry and cytology from fine needle aspirates of breasts from women at high risk for breast cancer". 11th Annual San Antonio Breast Cancer Symposium, Texas, November 29 30, 1988.


  1. Martino, S., Gala, R., Valeriote, F., Kim, P., Heilbrun, L., Kresge, C., Boomer, A. "Prolactin as a predictor of breast cancer risk". 11th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, November 29 30, 1988.

18. Martino, S. "Research In Breast Cancer Prevention". Presented at Women Physicians on Medical Issues, Ohio University College of Osteopathic Medicine, Athens, Ohio, April 1, 1989.


19. Martino, S., Ensley, J., Weaver, D., Benitez, P., An, T., Maciorowski, Z., deBraud, F., Hassan, M., KuKuruga, M., Singhakowinta, A., Valeriote, F. "Cellular DNA content characteristics of needle aspirates from patients at high risk for developing breast cancer". American Association for Cancer Research, San Francisco, California, May 24 27, 1989.
20. Martino, S. "The Oncologist's Role in Breast Cancer". The American Osteograthic College of Radiology Meeting, Chicago, June 1989.


  1. Martino, S. "Diet and Breast Cancer Prevention". The American Osteograthic College of Radiology Meeting, Chicago, June 1989.

22. Boomer, A., Martino, S., Krag, G., Liang, D., Bacus, J., Reading, B., Heilbrun, L. "Compliance to a 15% fat diet in women at risk for breast cancer". 12th Annual San Antonio Breast Cancer Symposium. San Antonio, Texas, December, 1989.


23. Flaherty, L., Robinson, W., Redman, B., Gonzales, R., Martino, S., Kraut, M., Valdivieso, M. and Rudolph, A. "A phase I study of dacarbazine (DTIC), cisplatin (DDP), and outpatient interleukin 2 (IL 2) (RIDD 2) in metastatic malignant melanoma (M.M.M.)". ASCO, Washington, D.C., May, 1990.
24. Martino, S. "Coagulation effects and thrombophlebitis of Tamoxifen". Presented at the Tamoxifen Health Trial Network Meeting, Madison, Wisconsin. Sponsored by the University of Wisconsin Clinical Cancer Center. June, 1990.
25. Martino, S. "Breast cancer prevention with Tamoxifen". Presented to SWOG Breast Committee Scientific Session, Columbus, Ohio, October 3, 1990.
26. Lemanne, D., Simon, M., Martino, S., Swanson, M. "Breast carcinoma in situ (CIS): Greater rise in ductal carcinoma in situ (DCIS) vs. lobular carcinoma in situ (LCIS)". ASCO, Houston, TX, March 1991.
27. Chlebowski, R.T., Rose, D., Blackburn, G., Buzzard, M., Khandekar, J., York, R., Insull, W., S., Martino, Elashoff, R., Wynder, E. Feasibility of using dietary fat intake reduction in adjuvant breast cancer management. ASCO Houston, TX, March 1991.
28. Redman, B., Flaherty, L., Chou, T.H., Kraut, M., Martino, S., Simon, M., Groves, E. Phase I trial of recombinant macrophage colony stimulating factor (M CSF) by rapid intravenous (IV) infusion in patients with cancer. ASCO, Houston, TX, March 1991.
29. Simon, M., Schwartz, A., Martino, S., Swanson, M. Trends in the diagnosis of in situ breast cancer in the Detroit Metropolitan Area. ASCO, Houston, TX, March 1991.
30. Kraut, M., Wozniak, A., Flaherty, L., Redman, B., Samal, B., Martino, S., Simon, M., Valdivieso, M. Treatment of metastatic non small cell lung cancer (NSCLC) with mitomycin, etoposide, and cisplatin (MEP). ASCO, Houston, TX, March 1991.
31. Simon, M., Lemanne, D., Martino, S., Schwartz, A., Swanson, G.M. Trends in the incidence of in situ and invasive breast cancer in the Detroit Metropolitan Area. 14th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 6-7, 1991.
32. Ensley, J., Weaver, D., Benitez, P., An, T., Maciorowski, Z., Alonso, M., Kukuruga, M., Martino, S. Dietary modulation of abnormal DNA histograms from breast aspirates of women at high risk for developing breast cancer. First International Cancer Molecular Biology Symposium, Cairo, Egypt, December 1-3, 1992.
33. Djuric, Z., Simon, M.S., Luongo, D.A., LoRusso, P.M. & Martino, S. Levels of 5-hydroxymethyl-2'-deoxyuridine in blood DNA as a marker of breast cancer risk. American Association of Cancer Research, April 1994, San Francisco.
34. A. Lichter, S. Green, K. Albain, L. Hutchins, S. Martino. The Influence of Patient Characteristics, Socioeconomic (SES) Factors, Geography, and Systemic Risk on the Use of Breast Sparing Treatment in the Adjuvant Breast Cancer Studies. ASCO meeting, May 14-17,1994, Dallas, TX.
35. Taylor CW, Green S, Dalton WS, Martino S, Ingle JN, Robert NJ, Rector DJ, Osborne CK, (and Participating Investigators of the Southwest Oncology Group, North Central Cancer Treatment Group and Eastern Cooperative Oncology Group). A Multi-Center Randomized Trial of Zoladex Versus Surgical Ovariectomy in Pre-Menopausal Patients with Receptor Positive Metastatic Breast Cancer. 18th Annual San Antonio Breast Cancer Symposium, December 8-13, 1995, San Antonio, TX.
36. Taylor CW, Green S, Dalton WS, Martino S, Ingle JN, Robert NJ, Osborne CK (and Participating Investigators of the Southwest Oncology Group, North Central Cancer Treatment Group and Eastern Cooperative Oncology Group). Phase 3, Randomized, Multi-Center Comparison of Zoladex Versus Surgical Ovariectomy in Premenopausal Patients with Receptor Positive Metastatic Breast Cancer (to be presented at the Sixth International Congress on Anti-Cancer Treatment, February 6-9, 1996, Palais Des Congres, Paris, France)
37. Martino, S. Adjuvant Therapy of Breast Cancer, Allen Zieger Memorial Lecture Series. Botsford Hospital, Farmington, Michigan, October, 1997.
38. Martino, S. “Breast Cancer Prevention”, Sponsored by SWOG Cancer Control Committee, SWOG meeting, April 1998.
39. Martino, S. “Breast Cancer update Sponsored by Bristol Myer-Squibb, Data Managers Educational Synposium, St. Louis, Missouri. June 1998.


  1. Martino, S. LHRH Agonists Sponsored by Zeneca Pharmaceuticals, Speaker Bureau Training Program, West Palm Beach, Florida. June 1998.




  1. Martino, S. Management of Metastatic Disease and Controversies in Breast Cancer, presented at Medical Oncology of Breast Cancer Fellows Program, Sponsored by University of Texas, M.D. Anderson Cancer Center, July 1998.




  1. Martino, S. New Developments in Adjuvant Management of Breast Cancer, presented to Piedmont Oncology Association, 19th Annual Symposium, Sponsored by Wake Forest University, October 1998.



  2. Martino, S. “Latest Data on the use of Tamoxifen in Treatment”, presented at Breast Cancer Speakers Update - Zeneca Pharmaceutical – Scottsdale, AZ, April 9-10, 1999.




  1. Martino, S. “Metastatic Therapy – Treatment”, presented at the Medical Oncology of Breast Cancer Fellows Program – Sponsored by University of Texas, M.D. Anderson Cancer Center, July 1999.




  1. Martino, S. “Breast Cancer Therapy – Approaching the New Millennium” – Sponsored by Network for Medical Communication & Research. Washington, DC., May 6, 2000.




  1. Martino, S. “High Dose Chemotherapy”, presented at ASCO, Poster Discussion Session. New Orleans, Lousiana, May 22, 2000.




  1. Martino, S. “Metastatic Breast Cancer – The Role of Gemzar” Sponsored by Network for Medical Communication & Research. Englewood, CO., August 25 – 26, 2000.




  1. Noe LN, Becker RV, Gore M, Martino S, Eiremann W, Namer M, Howell T, Bianco AR, Wantanabe T, Chen DM, “An Approach to Designing a Multi-National Model for the Current Treatment of Breast Cancer”. Poster Presentation, ISPOR Third Annual European Conference. Antwerp, Belgium. November 5 – 7, 2000.




  1. Martino, S. “NOCR’s 2001 ASCO Highlights Program” Sponsored by Network for Medical Communications and Research. Las Vegas, NV. June 22-23, 2001.




  1. Martino, S. “NOCR’s 2001 ASCO Highlights Program” Sponsored by Network for Medical Communications and Research, Delray Beach, FL. June 29-30, 2001




  1. Martino, S. ”Challenging Cases in Patient Management” Sponsored by Network for Medical Communication and Research, Las Vegas, NV. September 8, 2001.




  1. Martino, S. “A Phase III Trial of Taxol (T)/Doxorubicin/Cytoxan (D) (Two Dose Levels) Versus Doxorubicin/Cytoxan (C) Followed by a Comparison of Weekly Versus Q3 Weekly T in Patients (pts) with Metastatic Breast Cancer (MBC”). Presented at ASCO Poster Discussion, Orlando, FL, May 18-21, 2002.




  1. McNabb M, Martino S, Secrest RJ, Bryant K, Blatter J, Powles T, Mershon J, “Baseline Breast Cancer Risk Demographics and Methodology for the Raloxifene Use for The Heart (RUTH) and Continuing Outcomes Relevant to Evista (CORE) Studies, Two Breast Cancer Prevention Trials”. Presented at the 13th International Meeting of The European Society of Gynecologic Oncology, Brussels, April 8, 2003.




  1. Albain KS, Unger JM, Hutchins LF, Rivkin SE, Martino S, Livingston RB, Osborne CK. “Outcome of African Amercans on Southwest Oncology Group (SWOG) breast cancer adjuvant therapy trials”. Presented at the 26th Annual San Antonio Breast Cancer Symposium, December 3-6, 2003.




  1. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pater JL. Randomized placebo-controlled trial of letrozole in postmenopausal women with early breast cancer completing five years of tamoxifen. Presented at the 26th Annual San Antonio Breast Cancer Symposium, December 3-6, 2003.



  1. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon JL, Disch D, Secrest RJ, Cummings SR. Incidence of invasive breast cancer following 8 years of raloxifene therapy in postmenopausal women with osteoporosis: Results from the Continuing Outcomes Relevant to Evista (CORE) trial. ASCO Oral Presentation, New Orleans, LA, June 5-8, 2004.




  1. Cauley JA, Martino S, Barrett-Connor E, Powles TJ, Mershon JL, Disch D, Secrest RJ, Cummings SR. Effect of raloxifene on invasive breast cancer incidence in postmenopausal women stratified by Gail risk assessment: Results of the Continuing Outcomes of Relevant to Evista® (CORE) trial. ASCO General Poster Session, New Orleans, LA, June 5-8, 2004.




  1. Martino S, Powles T, Cauley J, Mershon J, Disch D, Secrest R, Cummings S. Effect of raloxifene on incidence of invasive breast cancer in postmenopausal women stratified by baseline serum estradiol: Results of the Continuing Outcomes Relevant to Evista® trial. 26th San Antonio Breast Cancer Symposium, Abstracts – General Oral Session, December 8-11, 2004.




  1. Martino S, Disch D, Dowsett S, Mershon J. Raloxifene and breast cancer risk reduction based on breast cancer family history. The American College of Obstetrics and Gynecology 53rd Annual Clinical Meeting Oral Presentation, San Francisco, CA, May 7–11, 2005.




  1. Martino S, Disch D, Dowsett S, Mershon J. Effect of raloxifene on invasive breast cancer incidence in postmenopausal women stratified by age (<65 and >65 years). ASCO General Poster Session, Orlando, FL, May 13–17, 2005.




  1. Perez EA, Suman VJ, Davidson N, Martino S, Kaufman P. NCCTG N9831 (Presenter: Perez EA) ASCO Education Session: Advances in Monoclonal Antibody Therapy for Breast Cancer, Orlando, FL, May 13–17, 2005.




  1. Romond EH, Perez EA, Bryant J, Suman V, Geyer CE, Davidson N, Tan-Chiu E, Martino S, Swain SM, Kaufman P, Feherenbacher L, Pisansky T, Vogel V, Kutteh LA, Yothers G, Visscher D, Brown AM, Jenkins R, Seay TE, Mamounas E, Abrams J, Wolmark N. Doxorubicin and cyclophosphamide follwed by paclitaxel with or with0ut trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer. Combined analysis of NSABP-B31/NCCTG-N9831. (Presenter: Romond EH) ASCO Education Session: Advances in Monoclonal Antibody Therapy for Breast Cancer, Orlando, FL, May 13–17, 2005.




  1. Martino S. Breast Cancer Research. ACOI: 67th Annual Convention and Scientific Sessions
    October 10-14, 2007, Boston, MA




  1. Martino S. Decreasing the Continued Risk of Recurrence: Extended Adjuvant Endocrine Therapy Update. Novartis: US Speaker Update Meeting, San Francisco, CA, July 17, 2008.




  1. Martino S. “Magnetic Resonance Imaging (MRI) for the Diagnosis and Staging of Breast Cancer”, American College of Osteopathic Internists (ACOI) 68th Annual Convention and Scientific Sessions, Marco Island, FL, November 1, 2008.




  1. Martino S. “Breast Cancer: Trial Updates & Current Recommendations” 2009 Annual Clinical Assembly of Osteopathic Surgeons. Chicago, IL, November 1, 2009.




Yüklə 231,71 Kb.

Dostları ilə paylaş:
1   2   3   4



Verilənlər bazası müəlliflik hüququ ilə müdafiə olunur ©muhaz.org 2024
rəhbərliyinə müraciət
gir | qeydiyyatdan keç
    Ana səhifə
Dərs
Dərslik
Guide
Kompozisiya
Mücərrəd
Mühazirə
Qaydalar
Referat
Report
Request
Review

yükləyin